大麻消费的当代路线

Julianne Moy
{"title":"大麻消费的当代路线","authors":"Julianne Moy","doi":"10.7556/jaoa.2019.087","DOIUrl":null,"url":null,"abstract":"I would first like to commend Peters and Chien on the concise information they provided regarding the modalities, forms, and dosing of cannabis in their February 2018 article on cannabis. I agree with the authors that cannabis use will become even more omnipresent in medicine than it already is. However, I strongly disagree and even refute their statement that “Physicians have little reason to advocate for cannabis use, as data are limited on its beneficial effects.” I am a cannabis clinician in Ohio, which means that I have a certificate to recommend medical marijuana in the state. Medical marijuana legislation was passed in Ohio in 2016, and the state is currently in the early stages of rollout: patient registries opened December 2018, in-state grown cannabis greenhouses have cultivated their first harvests, and the first dispensaries opened in February 2019. It is a very exciting time for cannabis in Ohio, so I was disheartened when this article came across my desk. I agree that there is limited evidencebased literature regarding cannabis currently, but existing data coupled with current ongoing research are more than positive. The National Institutes of Health have been funding Israeli cannabis research since the early 1960s. In a 2018 review, Tashkin concluded that smoking marijuana habitually did not increase the likelihood of lung cancer, possibly because of the immunoprotectant properties of cannabis. Additionally, evidence has shown that cannabis is a safer alternative to opioids; in the face of the ongoing opioid epidemic, this news is welcoming. Cannabis has also been shown to be beneficial in acute opioid withdrawal and as a harm reduction tool in opioid use disorder. Furthermore, in June 2018, Epidiolex (GW Pharmaceuticals plc) was the first drug approved by the Food and Drug Administration that contains a purified substance derived from cannabis to treat patients with seizures associated with Lennox-Gastaut and Dravet syndromes. The evidence is growing, but we must be vigilant in our search and not be blinded by long-antiquated societal views. Yes, clinicians will have the challenge of keeping up with the ever-evolving use of cannabis, both medically and recreationally, but this challenge is one I gladly accept. (doi:10.7556/jaoa.2019.087)","PeriodicalId":16639,"journal":{"name":"Journal of Osteopathic Medicine Journal of Osteopathic Medicine","volume":"52 1","pages":"477 - 477"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Contemporary Routes of Cannabis Consumption\",\"authors\":\"Julianne Moy\",\"doi\":\"10.7556/jaoa.2019.087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"I would first like to commend Peters and Chien on the concise information they provided regarding the modalities, forms, and dosing of cannabis in their February 2018 article on cannabis. I agree with the authors that cannabis use will become even more omnipresent in medicine than it already is. However, I strongly disagree and even refute their statement that “Physicians have little reason to advocate for cannabis use, as data are limited on its beneficial effects.” I am a cannabis clinician in Ohio, which means that I have a certificate to recommend medical marijuana in the state. Medical marijuana legislation was passed in Ohio in 2016, and the state is currently in the early stages of rollout: patient registries opened December 2018, in-state grown cannabis greenhouses have cultivated their first harvests, and the first dispensaries opened in February 2019. It is a very exciting time for cannabis in Ohio, so I was disheartened when this article came across my desk. I agree that there is limited evidencebased literature regarding cannabis currently, but existing data coupled with current ongoing research are more than positive. The National Institutes of Health have been funding Israeli cannabis research since the early 1960s. In a 2018 review, Tashkin concluded that smoking marijuana habitually did not increase the likelihood of lung cancer, possibly because of the immunoprotectant properties of cannabis. Additionally, evidence has shown that cannabis is a safer alternative to opioids; in the face of the ongoing opioid epidemic, this news is welcoming. Cannabis has also been shown to be beneficial in acute opioid withdrawal and as a harm reduction tool in opioid use disorder. Furthermore, in June 2018, Epidiolex (GW Pharmaceuticals plc) was the first drug approved by the Food and Drug Administration that contains a purified substance derived from cannabis to treat patients with seizures associated with Lennox-Gastaut and Dravet syndromes. The evidence is growing, but we must be vigilant in our search and not be blinded by long-antiquated societal views. Yes, clinicians will have the challenge of keeping up with the ever-evolving use of cannabis, both medically and recreationally, but this challenge is one I gladly accept. (doi:10.7556/jaoa.2019.087)\",\"PeriodicalId\":16639,\"journal\":{\"name\":\"Journal of Osteopathic Medicine Journal of Osteopathic Medicine\",\"volume\":\"52 1\",\"pages\":\"477 - 477\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Osteopathic Medicine Journal of Osteopathic Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7556/jaoa.2019.087\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Osteopathic Medicine Journal of Osteopathic Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7556/jaoa.2019.087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

首先,我要赞扬Peters和Chien在2018年2月关于大麻的文章中提供的关于大麻的方式、形式和剂量的简明信息。我同意作者的观点,大麻的使用将在医学中变得比现在更无所不在。然而,我强烈反对甚至反驳他们的说法,即“医生没有理由提倡使用大麻,因为有关其有益效果的数据有限。”我是俄亥俄州的一名大麻临床医生,这意味着我有在该州推荐医用大麻的证书。2016年,俄亥俄州通过了医用大麻立法,该州目前正处于推广的早期阶段:2018年12月开放患者登记,州内种植的大麻温室已经收获了第一批大麻,第一批药房于2019年2月开业。这是俄亥俄州大麻的一个非常激动人心的时刻,所以当这篇文章出现在我的办公桌上时,我感到很沮丧。我同意目前关于大麻的循证文献有限,但现有数据加上目前正在进行的研究非常积极。自20世纪60年代初以来,美国国立卫生研究院一直在资助以色列的大麻研究。在2018年的一篇综述中,塔什金得出结论,习惯性吸食大麻不会增加患肺癌的可能性,这可能是因为大麻具有免疫保护作用。此外,有证据表明,大麻是阿片类药物更安全的替代品;面对持续的阿片类药物流行,这一消息是受欢迎的。大麻也已被证明对急性阿片类药物戒断有益,并可作为减少阿片类药物使用障碍危害的工具。此外,2018年6月,Epidiolex (GW Pharmaceuticals plc)是美国食品和药物管理局批准的第一种含有从大麻中提取的纯化物质的药物,用于治疗与lenox - gastaut和Dravet综合征相关的癫痫发作患者。证据越来越多,但我们必须保持警惕,不要被长期过时的社会观点所蒙蔽。是的,临床医生将面临挑战,要跟上大麻在医疗和娱乐方面不断发展的使用,但我很高兴接受这一挑战。(doi: 10.7556 / jaoa.2019.087)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Contemporary Routes of Cannabis Consumption
I would first like to commend Peters and Chien on the concise information they provided regarding the modalities, forms, and dosing of cannabis in their February 2018 article on cannabis. I agree with the authors that cannabis use will become even more omnipresent in medicine than it already is. However, I strongly disagree and even refute their statement that “Physicians have little reason to advocate for cannabis use, as data are limited on its beneficial effects.” I am a cannabis clinician in Ohio, which means that I have a certificate to recommend medical marijuana in the state. Medical marijuana legislation was passed in Ohio in 2016, and the state is currently in the early stages of rollout: patient registries opened December 2018, in-state grown cannabis greenhouses have cultivated their first harvests, and the first dispensaries opened in February 2019. It is a very exciting time for cannabis in Ohio, so I was disheartened when this article came across my desk. I agree that there is limited evidencebased literature regarding cannabis currently, but existing data coupled with current ongoing research are more than positive. The National Institutes of Health have been funding Israeli cannabis research since the early 1960s. In a 2018 review, Tashkin concluded that smoking marijuana habitually did not increase the likelihood of lung cancer, possibly because of the immunoprotectant properties of cannabis. Additionally, evidence has shown that cannabis is a safer alternative to opioids; in the face of the ongoing opioid epidemic, this news is welcoming. Cannabis has also been shown to be beneficial in acute opioid withdrawal and as a harm reduction tool in opioid use disorder. Furthermore, in June 2018, Epidiolex (GW Pharmaceuticals plc) was the first drug approved by the Food and Drug Administration that contains a purified substance derived from cannabis to treat patients with seizures associated with Lennox-Gastaut and Dravet syndromes. The evidence is growing, but we must be vigilant in our search and not be blinded by long-antiquated societal views. Yes, clinicians will have the challenge of keeping up with the ever-evolving use of cannabis, both medically and recreationally, but this challenge is one I gladly accept. (doi:10.7556/jaoa.2019.087)
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信